Probiodrug Ag

Forschungszentrum Juelich Gmbh

Forschungszentrum Julich Gmbh

Martin Kleinschmidt

Stephan Schilling

Jens-Ulrich Rahfeld

Hans-Ulrich Demuth

Sonja Kampfer

Anita Reisenauer-Schaupp

Stephen D Gillies

Kathrin Gans

Anke Piechotta

Kristin Ebermann

Dieter Willbold

Susanne Aileen Funke

Dirk Bartnik

Kathrin Gnoth

Yeliz Cinar

Hans-Henning Ludwig

Astrid Kehlen

Monique Haegele

The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A&#x3b2; N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A&#x3b3; N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.

Humanized antibodies

The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A&#x3b2; N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A&#x3b2; N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.

Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.

Uses of antibodies directed against amyloid-&#x3b2;

Diagnostic antibody assay

Peptides that bind to amino-terminal truncated pEA&#x3b2;3-42, the free glutamic acid residue of which lies in position 3 or 11 in the form of cyclized pyroglutamate. Four oligopeptides were identified using mirror image phage display technology.

Peptides that bind to amino-truncated amyloid-beta-peptide and use of said peptides

Diagnostic assays for the diagnosis of amyloidosis, in particular, Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.

The present invention pertains to novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.

Antibodies specific for N-terminal truncated and pyroglutamate modified amyloid-beta peptides

Growing community of inventors

Halle/Saale, Germany

Martin Kleinschmidt